Skip to main content
19/05/2022

A work led by Dr. Raul Herance wins an award at the European Molecular Imaging Meeting

Premi EMIM Dr. Raul Herance

19/05/2022

The head of the Medical Molecular Imaging group at VHIR received the recognition for the best poster presentation for a study on myocardial insulin resistance and cardiovascular risk.

Dr. J Raul Herance, head of the Medical Molecular Imaging group at Vall d'Hebron Research Institute (VHIR) has received the award for best poster presentation at the European Molecular Imaging Meeting (EMIM 2022) in the Metabolic Imaging category, for the paper "Phenotyping type 2 diabetes in terms of myocardial insulin resistance and its potential cardiovascular consequences: a new strategy based on 18F-FDG PET/CT" published in the Journal of Personalized Medicine.

The study, led by the Medical Molecular Imaging and Diabetes and Metabolism groups at VHIR, identified that 60% of patients with controlled type 2 diabetes have myocardial insulin resistance and as a consequence have structural changes in the myocardium and more calcifications in the coronary arteries, thus more cardiovascular risk.

Researchers have developed an innovative methodology that allows precise determination of insulin resistance in myocardium in vivo through PET/CT, which has made it possible to phenotype patients with type 2 diabetes into two groups, while determining structural alterations in the heart and calcifications in the coronary arteries. Calcifications in the coronary arteries are one of the main risk factors for cardiovascular complications. For this reason, it has been possible to relate that patients with myocardial insulin resistance would be more likely to suffer this type of events.

European Molecular Imaging Congress

The European Molecular Imaging Meeting (EMIM) is the annual meeting of the European Molecular Imaging Society. More than 800 international professionals dedicated to medical imaging in biomedicine attended the 17th edition, held last March in Thessaloniki (Greece). In total, 218 posters were presented, among which 5 prizes were awarded.

Related news

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

Phase IV AI is included in the Horizon Europe programme, lasts 3 years and prioritises data security and privacy compliance.

This investment from EIT Health in the project will enable D-Sight to progress in the clinical development of its groundbreaking treatment for the early stages of diabetic retinopathy.

Related professionals

Mónica Sánchez Bartrés

Mónica Sánchez Bartrés

Research technician
Diabetes and Metabolism
Read more
Irene Hernández Hernández

Irene Hernández Hernández

Predoctoral researcher
Diabetes and Metabolism
Read more
Judit Amigó Farran

Judit Amigó Farran

Predoctoral researcher
Diabetes and Metabolism
Read more
Garcia Arabehety, Julia

Garcia Arabehety, Julia

Research technician
Diabetes and Metabolism
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.